What Noxopharm does

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage biotechnology company founded in 2015 and headquartered in Castle Hill, NSW, developing novel therapeutics across oncology, autoimmune/inflammatory disease, and mRNA vaccine enhancement. The company operates two proprietary technology platforms: Sofra™, an oligonucleotide-based platform using short nucleic acid sequences to amplify Toll-like receptor 8 (TLR8) activity, which the company reports achieves more than 200-fold activity improvement over current best-in-class clinical comparators in human skin biopsies; and Chroma™, a small-molecule platform generating multiple oncology drug candidates, with leading preclinical asset CRO-67 positioned for pancreatic cancer.

The company's clinical pipeline centres on Veyonda®, which is in a Phase 1 investigator-initiated trial for cancer in combination with immunotherapy, alongside earlier-stage assets including CRO-67 (Chroma™ platform, pancreatic cancer preclinical) and SOF-VAC (Sofra™ platform, mRNA vaccine safety/efficacy improvement). Noxopharm is pre-revenue with no marketed products; its economic model is structured around a dual-track strategy of developing selected compounds in-house while pursuing external commercial arrangements (out-licensing, co-development, and partnerships with pharmaceutical companies) for other assets. The corporate group comprises Noxopharm Limited as the listed parent and wholly-owned subsidiary Pharmorage Pty Limited (a drug delivery/formulation entity). Recent strategic milestones include the granting of US patent protection for the Sofra™ platform in October 2025 and the May 2026 disclosure of new TLR8 amplification data, signalling continued platform validation and US-market intent.

Name

Noxopharm

Legal name

Noxopharm Limited

Website

https://noxopharm.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage biotech developing oligonucleotide (Sofra™) and small-molecule (Chroma™) drug candidates for cancer, autoimmune/inflammatory disease, and mRNA vaccine enhancement, with lead asset Veyonda® in Phase 1 oncology trials.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceutical drug development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC)

Keywords

• Clinical stage drug development
• Immuno-oncology therapeutics
• Oligonucleotide based therapies
• Small molecule oncology
• MRNA vaccine enhancement

Headquarters

HQ city

Turramurra

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-revenue R&D / future licensing: Noxopharm is a clinical-stage biotech with no products on the market and therefore no product revenue. The company's economic model relies on capital raises (as an ASX-listed entity) and is structured around developing a pipeline of proprietary drugs across multiple platforms, with the explicit intent to develop certain compounds in-house while pursuing external commercial arrangements (licensing/out-licensing deals, co-development) for others. Future revenue is expected to be derived from licensing royalties, milestone payments, and eventual drug sales once candidates (Veyonda®, CRO-67, SOF-VAC) reach market.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Noxopharm is a clinical-stage Australian biotech that develops novel drug candidates for cancer and inflammation through two proprietary technology platforms: Sofra™, an oligonucleotide-based platform that amplifies Toll-like receptor 8 (TLR8) activity for immuno-oncology, autoimmune/inflammatory disease, and mRNA vaccine enhancement, and Chroma™, a small-molecule oncology platform producing candidates such as preclinical CRO-67 for pancreatic cancer. Its lead clinical asset Veyonda® is currently being evaluated in a Phase 1 investigator-initiated trial for cancer in combination with immunotherapy, while the SOF-VAC program applies the Sofra™ platform to improve the safety profile of mRNA vaccines and therapeutics.

Product overview

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company built on a multi-platform architecture rather than a single unified product. Its portfolio is anchored by two proprietary technology platforms — Sofra™, an oligonucleotide-based platform (short nucleic acid sequences) targeting inflammation, autoimmunity, mRNA drug enhancement and immuno-oncology (including TLR8-amplifying compounds), and Chroma™, a small-molecule platform driving multiple cancer drug candidates. On top of these platforms sits Veyonda®, the company's lead clinical drug candidate currently in a Phase 1 investigator-initiated trial for cancer in combination with immunotherapy, while preclinical assets such as CRO-67 (from Chroma™, focused on pancreatic cancer) and application modules like SOF-VAC (mRNA vaccine improvement under Sofra™) extend the pipeline across cancer and inflammatory disease indications.

Differentiator

Problem solved

Functional benefit

Brands

• Sofra™: Technology platform with a pipeline of new proprietary drugs based on oligonucleotides (short strands of DNA/RNA building blocks), focused on mRNA vaccines and therapeutics, autoimmune disease and immuno-oncology.
• Chroma™
• Veyonda®

Products and services

• Sofra™ Sofra™ is an oligonucleotide-based technology platform using short nucleic acid sequences that amplifies Toll-like receptor 8 (TLR8) activity, with applications spanning mRNA vaccine enhancement, autoimmune and inflammatory disease treatment, and immuno-oncology. It serves as the foundation for a pipeline of new proprietary drug candidates and is supported by granted US patent protection.
• Chroma™ Chroma™ is a small-molecule technology platform focused on developing multiple drug candidates primarily for cancer treatment, with leading preclinical candidate CRO-67 showing promising signals for the treatment of pancreatic cancer.
• Veyonda® Veyonda® is Noxopharm's clinical-stage drug candidate currently in a Phase 1 investigator-initiated clinical trial for the treatment of cancer in combination with immunotherapy.
• CRO-67 CRO-67 is the leading preclinical drug candidate from Noxopharm's Chroma™ small-molecule platform, showing promising signals for the treatment of pancreatic cancer.
• SOF-VAC SOF-VAC is an application program of the Sofra™ platform aimed at improving the safety profile and effectiveness of mRNA vaccines and therapeutics by reducing side effects and enhancing safety.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Pharmorage Pty LimitedcoreStrategic or Co-development PartnerPharmorage Pty Limited (ACN 641 047 403) is listed as part of the Noxopharm Group of companies in Noxopharm's Privacy Policy and is featured as a dedicated page under the About Us section of the company's website. The Privacy Policy expressly states that the policy applies to each company in the Noxopharm Group, indicating Pharmorage is a related corporate entity operating within the same group structure.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MiNA Therapeutics: Clinical-stage UK biotech developing RNA-based therapeutics that engage innate immune pathways, including TLR8 agonism in oncology. Directly comparable to Noxopharm's Sofra™ platform as one of the few companies publicly pursuing oligonucleotide-based TLR8 immuno-oncology strategies.
• Imugene: Australian (ASX-listed) clinical-stage immuno-oncology company with a pipeline of B-cell vaccines, oncolytic viruses, and combination immunotherapies. Most directly comparable ASX peer in terms of size, stage, and immuno-oncology focus, allowing direct read-across on clinical and capital-markets dynamics.
• Bolt Biotherapeutics: US clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates that activate myeloid and antigen-presenting cells in the tumour microenvironment. Comparable to Noxopharm's ambition of combining tumour-targeting with immune activation, though using a different payload architecture.

Emerging players

• Compugen: Clinical-stage immuno-oncology company using computational discovery to identify novel drug targets and develop antibody-based therapeutics. Comparable in therapeutic area and stage, and provides a useful read-across for AI-driven target discovery applied to immune checkpoints and tumour microenvironment.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company with self-amplifying RNA technology and partnerships in vaccines and rare disease. Comparable as a smaller, technology-focused mRNA company that partners with larger pharma, mirroring the out-licensing model Noxopharm intends to use for SOF-VAC.
• Werewolf Therapeutics: US clinical-stage biotech developing tumour-activated immune-stimulating prodrugs (PREDATOR platform) for immuno-oncology. Comparable as an early-stage company engineering conditional immune activation in the tumour microenvironment, similar in spirit to Noxopharm's combination-immunotherapy positioning.

Broad incumbents

• BioNTech: Global leader in mRNA therapeutics and vaccines with deep immuno-oncology pipeline. Relevant as a broad incumbent for the SOF-VAC mRNA-vaccine enhancement opportunity and as a benchmark for valuation of immuno-oncology platforms at scale.
• Moderna: Global mRNA platform company with commercial COVID-19 vaccine and an oncology pipeline. Provides relevant context for the mRNA-enhancement and oncology applications of Noxopharm's SOF-VAC program and for sizing the long-term opportunity if Sofra™ becomes a standard mRNA adjuvant.

Regional players

• Telix Pharmaceuticals: Australian (ASX-listed) commercial-stage biopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals for cancer. Comparable as a successful Australian oncology biotech but at a much later commercial stage; provides relevant comparables on Australian biotech valuation and capital-markets access.
• PharmAust: Australian (ASX-listed) clinical-stage biotech developing small-molecule oncology drugs, including for pancreatic cancer. Comparable as a domestic Australian clinical-stage peer with oncology focus, although the underlying mechanism (Chroma™ small molecules) is mechanistically distinct.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/watch?v=2f9adjZDKlw
• Xx.com/noxopharm
• LinkedInlinkedin.com/company/noxopharm-limited

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noxopharm